GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024
GT Biopharma, Inc. (NASDAQ: GTBP) has announced a virtual KOL event scheduled for October 10, 2024 at 12:00 PM ET. The event will feature Dr. Jeffrey Miller and Dr. Mark Juckett from the University of Minnesota Medical School, who will discuss the NK cell therapy landscape and its potential beyond oncology.
Dr. Miller will focus on GT Biopharma's TriKE® platform and its extensive pipeline of NK cell engagers. Dr. Juckett will address the upcoming Phase 1 trial of GTB-3650 for acute myeloid leukemia (AML) treatment, expected to start in Q4.
The event aims to provide insights into current limitations and future directions of NK cell therapy, including its potential in inflammatory autoimmune indications. A live Q&A session will follow the presentation.
GT Biopharma, Inc. (NASDAQ: GTBP) ha annunciato un evento virtuale con esperti programmato per 10 ottobre 2024 alle 12:00 ET. L'evento presenterà il Dr. Jeffrey Miller e il Dr. Mark Juckett della University of Minnesota Medical School, i quali discuteranno del panorama della terapia con cellule NK e del suo potenziale oltre l'oncologia.
Il Dr. Miller si concentrerà sulla piattaforma TriKE® di GT Biopharma e sul suo ampio pipeline di attivatori di cellule NK. Il Dr. Juckett affronterà il prossimo studio di Fase 1 di GTB-3650 per il trattamento della leucemia mieloide acuta (AML), previsto per iniziare nel quarto trimestre.
L'evento mira a fornire approfondimenti sulle attuali limitazioni e le future direzioni della terapia con cellule NK, inclusa la sua potenzialità in indicazioni autoimmuni infiammatorie. Seguirà una sessione di domande e risposte dal vivo dopo la presentazione.
GT Biopharma, Inc. (NASDAQ: GTBP) ha anunciado un evento virtual con líderes de opinión programado para el 10 de octubre de 2024 a las 12:00 PM ET. El evento contará con el Dr. Jeffrey Miller y el Dr. Mark Juckett de la Escuela de Medicina de la Universidad de Minnesota, quienes discutirán el panorama de la terapia con células NK y su potencial más allá de la oncología.
El Dr. Miller se centrará en la plataforma TriKE® de GT Biopharma y su amplia cartera de activadores de células NK. El Dr. Juckett abordará el próximo ensayo de Fase 1 de GTB-3650 para el tratamiento de leucemia mieloide aguda (AML), que se espera que comience en el cuarto trimestre.
El evento tiene como objetivo proporcionar información sobre las limitaciones actuales y las direcciones futuras de la terapia con células NK, incluyendo su potencial en indicaciones autoinmunes inflamatorias. A continuación, habrá una sesión de preguntas y respuestas en vivo después de la presentación.
GT Biopharma, Inc. (NASDAQ: GTBP)가 2024년 10월 10일 오후 12시(ET)에 예정된 가상 KOL 이벤트를 발표했습니다. 이 행사에서는 미네소타 대학교 의과대학의 Jeffrey Miller 박사와 Mark Juckett 박사가 NK 세포 치료의 동향 및 종양학을 넘어선 잠재성에 대해 논의할 예정입니다.
Miller 박사는 GT Biopharma의 TriKE® 플랫폼과 NK 세포 결합제를 포함한 방대한 파이프라인에 집중할 것입니다. Juckett 박사는 급성 골수성 백혈병(AML) 치료를 위한 GTB-3650의 1상 시험에 대해 다룰 예정이며, 이는 4분기에 시작될 것으로 예상됩니다.
이 행사는 NK 세포 치료의 현재 한계와 미래 방향에 대한 통찰을 제공하는 것을 목표로 하며, 염증성 자가면역 적응증에 대한 잠재성도 포함됩니다. 발표 후에는 라이브 질의응답 세션이 이어질 예정입니다.
GT Biopharma, Inc. (NASDAQ: GTBP) a annoncé un événement virtuel avec des experts prévu pour le 10 octobre 2024 à 12h00 ET. Cet événement mettra en vedette le Dr. Jeffrey Miller et le Dr. Mark Juckett de l'École de Médecine de l'Université du Minnesota, qui discuteront du paysage de la thérapie par cellules NK et de son potentiel au-delà de l'oncologie.
Le Dr. Miller se concentrera sur la plateforme TriKE® de GT Biopharma et sur son large pipeline d'engageurs de cellules NK. Le Dr. Juckett abordera le prochain essai de Phase 1 de GTB-3650 pour le traitement de la leucémie myéloïde aiguë (AML), qui devrait commencer au quatrième trimestre.
Cette événement vise à fournir des informations sur les limites actuelles et les futures orientations de la thérapie par cellules NK, y compris son potentiel dans les indications auto-immunes inflammatoires. Une session de questions-réponses en direct suivra la présentation.
GT Biopharma, Inc. (NASDAQ: GTBP) hat ein virtuelles KOL-Event für den 10. Oktober 2024 um 12:00 Uhr ET angekündigt. Bei der Veranstaltung werden Dr. Jeffrey Miller und Dr. Mark Juckett von der University of Minnesota Medical School über die Therapielandschaft mit NK-Zellen und deren Potenzial über die Onkologie hinaus sprechen.
Dr. Miller wird sich auf die TriKE®-Plattform von GT Biopharma und sein umfangreiches Pipeline-Angebot an NK-Zell-Engagern konzentrieren. Dr. Juckett wird das bevorstehende Phase-1-Studie zu GTB-3650 zur Behandlung der akuten myeloischen Leukämie (AML) ansprechen, das voraussichtlich im vierten Quartal beginnen wird.
Das Event zielt darauf ab, Einblicke in die aktuellen Einschränkungen und künftigen Richtungen der NK-Zelltherapie zu geben, einschließlich ihres Potenzials bei entzündlichen Autoimmunerkrankungen. Im Anschluss an die Präsentation wird eine Live-Q&A-Session stattfinden.
- None.
- None.
SAN FRANCISCO, CALIFORNIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced it will host a virtual KOL event on Thursday, October 10, 2024 at 12:00 PM ET. To register, click here.
The event will feature Jeffrey Miller, MD1 and Mark Juckett, MD from the University of Minnesota Medical School2, who will give an overview of the NK cell therapy landscape, discuss current limitations and provide perspective on the future direction of the field as it expands into exciting new therapeutic areas beyond oncology including inflammatory autoimmune indications.
Dr. Miller will elaborate on GT Biopharma’s TriKE® platform which has created an extensive pipeline of NK cell engagers. He will define where these engagers may best fit into the broader therapeutic landscape. Dr. Juckett will speak to GT Biopharma’s Phase 1 trial expected to start in Q4 evaluating GTB-3650 monotherapy for the treatment of acute myeloid leukemia (AML).
A live question and answer session will follow the formal presentation.
- Dr. Miller is the Consulting Senior Medical Director at GT Biopharma and holds stock and options in GTBP.
- The University of Minnesota, pursuant to its license agreement with GT Biopharma, is entitled to receive royalties should commercial sales of GTB-3650 be realized. This interest has been reviewed and managed by the University of Minnesota in accordance with its conflict of interest policies.
About Jeffrey Miller, MD
Dr. Miller has been interested in NK cell biology, NK cell development, the acquisition of NK cell receptors and seamless translation into clinical trials throughout his entire academic career. Currently, the lab is focused on mechanisms which determine the enhanced function seen with CMV induced adaptive NK cells, facilitating immune synapses with IL-15 containing Trispecific Killer Engagers (TriKEs), IL-15 biology, NK cell killer immunoglobulin receptor (KIR) acquisition and function (NK cell education), and developing NK cell therapeutics.
Throughout his career at the University of Minnesota, he has mentored faculty and delivered hundreds of NK cells products to patients with cancer. His team has identified unique NKC2C+ NK cell repertoires exhibit a methylation signature of CD8+ T cells with properties of immune memory. Adaptive NK cells are distinctly different from canonical NK cells and signal through CD16 using a dominant CD3-zeta signal by downregulation of Fc-gamma R1. Adaptive NK cells are better primed for killing, cytokine production, ADCC and exhibit unique metabolic signatures that enhance their survival. He has developed state-of-the-art functional readouts to study NK cells from the laboratory and the clinic based on high resolution testing. He was the first to report that haploidentical allogeneic human NK cells can persist and expand for up to one month after adoptive transfer. Based on these studies a significant part of his effort is trying to understand how to exploit NK cells for therapeutic purposes against infection and cancer and how to improve outcomes from allogeneic hematopoietic cell transplantation.
Clinically, he has developed first-in-human trials using allogeneic donor NK cells, rhIL-15, IL-15/IL-15R alpha-Fc (ALT-803, now called N-803), an NK cell TriKE that engages NK cells and AML targets that costimulates NK cells with an IL-15 linker. Dr. Miller's experience and translational expertise has supported a transition from individual related donor NK cell products to induced pluripotent stem cell (iPSC) derived NK cells. Advantages of using this off-the-shelf platform include the flexibility of multiple gene edits, immediate cryopreserved product availability, multi-doing strategies and combinatorial therapy with targeted agents to enhance NK cell function.
Dr. Miller is devoted to team science and mentoring. He has supervised > 400 NK cell products and sponsored >10 INDs and his team has studied >4000 transplant patients. Dr. Miller's experience, NIH grants and translational expertise provides a rich environment for training.
About Mark Juckett, MD
Dr. Juckett is Professor of Medicine in the Division of Hematology, Oncology, and Transplantation at the University of Minnesota. His practice is committed to caring for people with blood cancers, especially when bone marrow transplantation or cellular therapy is required. In an era where the treatment options are expanding rapidly for patients with acute leukemia, myeloid diseases, and other blood cancers, Dr. Juckett believes the best care is determined after considering a patient and family's preferences and values. The Bone Marrow Transplant and Cell Therapy Program at the University of Minnesota strives to provide the best medical care possible through the innovative investigation into new and better treatment options and by incorporating discoveries into our daily medical care. His interest in helping people with blood cancers includes efforts to improve recovery through guided survivorship. The treatment of blood cancers can be a long and challenging journey for some people, who may be cured, but not recovered after treatment is complete. Dr. Juckett is also interested in developing survivorship care that will give patients and families the tools and support needed to regain a long, happy, and healthy life.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform. Our TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology. For more information, please visit gtbiopharma.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.
TriKE® is a registered trademark owned by GT Biopharma, Inc.
Investor Relations Contact:
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577
FAQ
When is GT Biopharma (GTBP) hosting its virtual KOL event?
What will be discussed at GT Biopharma's (GTBP) KOL event?
Who are the key speakers at GT Biopharma's (GTBP) virtual KOL event?
What is the focus of GT Biopharma's (GTBP) research?
When is GT Biopharma (GTBP) expected to start its Phase 1 trial for GTB-3650?
